Physician profile
Mark Marchitto
NPI 1134624000
$248,654.70
in general payments reported to CMS, 2019-2025
22 companies · $127K in 2025
The $127K reported for 2025 was more than what 98% of Dermatology providers received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $385 · 2023: $40K · 2024: $81K · 2025: $127K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $172K · Consulting Fee: $52K · Food and Beverage: $16K · Travel and Lodging: $8,082 · Education: $11.10.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $171,600.76 |
| Consulting Fee | $52,311.95 |
| Food and Beverage | $16,264.17 |
| Travel and Lodging | $8,081.99 |
| Education | $11.10 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Leo Pharma INC. | $191,406.28 | 2023-2025 | Adbry, Anzupgo, Spevigo |
| Pfizer INC. | $34,991.65 | 2022-2025 | |
| Janssen Biotech, INC. | $5,088.58 | 2023-2025 | Tremfya |
| Abbvie INC. | $4,798.78 | 2022-2025 | |
| Incyte Corporation | $3,944.19 | 2022-2025 | Opzelura, Opzelura |
| Ucb, INC. | $2,684.96 | 2022-2025 | Bimzelx |
| Arcutis Biotherapeutics, INC. | $1,975.83 | 2023-2025 | Zoryve |
| E.R. Squibb & Sons, L.L.C. | $1,013.27 | 2023-2025 | Sotyktu |
| Novartis Pharmaceuticals Corporation | $444.94 | 2023-2025 | |
| Lilly USA, LLC | $441.08 | 2022-2025 | Taltz, Ebglyss, Olumiant |
| Amgen INC. | $415.77 | 2023-2025 | Otezla, Otezla |
| Genzyme Corporation | $405.09 | 2023-2025 | |
| Sun Pharmaceutical Industries INC. | $206.39 | 2024-2025 | |
| Regeneron Healthcare Solutions, INC. | $196.23 | 2022-2025 | Dupixent |
| Dermavant Sciences, INC. | $191.26 | 2023-2024 | Vtama |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Galderma Laboratories, L.P. | $98.25 | 2024-2025 | Nemluvio |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $91.20 | 2023-2025 | Jublia, Cabtreo |
| Botanix Sb INC | $90.13 | 2025 | Sofdra |
| Organon LLC | $68.45 | 2025 | |
| Janssen Scientific Affairs, LLC | $45.70 | 2023-2024 | Tremfya |
| Epi Health, LLC | $36.86 | 2022 | |
| Helsinn Therapeutics (U.S.), INC. | $19.81 | 2023 | Valchlor |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Marchitto listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.